Published Date:
06 July 2009
BIOTECH firm NovaBiotics has received clearance from the Federal Institute for Drugs and Medical Devices and the Ethics Commission to commence first-in-man clinical trials of its lead product.
NovaBiotics, which is based in Aberdeen, is to start trials of its fungal nail treatment Novexatin, in a move that will take the firm a step closer to commercialisation of the product.
Dr Deborah O'Neil, who founded the company in 2004, said: "I am very pleased that we can announce the commencement of clinical trials for Novexatin."
She added: "We believe that, potentially, we have a world-leading treatment for fungal nail infections which will be more effective, safer and easier to use than any other product currently available, addressing this significant and poorly-met market."
Phase I of the trials is due to start immediately. NovaBiotics said it would make a further announcement about the commercialisation of the product "in due course".
The full article contains 161 words and appears in The Scotsman newspaper.
-
Last Updated:
05 July 2009 8:53 PM
-
Source:
The Scotsman
-
Location:
Edinburgh
